Zacks Research also compiles analyst ratings using a scale that ranges from 1 to 5.
Out of 15 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 9 rate it a "Buy", 0 "Sell", while 6 "Hold". Mean (EPS) target is set at $0.79. Finally, BlueMountain Capital Management LLC boosted its position in shares of Vertex Pharmaceuticals by 69.3% in the first quarter. Conning holds 0.02% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 5,740 shares. 8 given rating as a HOLD rating.0 reported as SELL recommendation and 0 issued UNDERWEIGHT rating. Fourteen investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The current stock price is $78.
The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) hit a new 52-week low and has $71.75 target or 8.00% below today's $77.99 share price. The stock had a trading volume of 675,386 shares. The company's 50-day moving average price is $84.48 and its 200-day moving average price is $89.41. That puts the market capitalization at $19.3 bln. The Stock has its 52-week High of $134.71 and 52-Week Low of $73.31 and it touched its 52-week high on Nov 23, 2015 and 52-Week Low on Nov 1, 2016.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Biotechnology exhibits an Operating Margin of -5.50% and a Gross Margin of 88.00%, therefore, displaying a Profit Margin of -14.20%.
FBI Reviewing Ties Between Trump's Ex-Campaign Manager And Russia, Ukraine
The Trump campaign reiterated that the investigation had proven what they already knew. Page has denied any connection, blaming Democrats for raising the issue.
Analysts also projected the Maximum, Minimum and Mean Earnings per share Estimate for Next Quarter. During the same period in the previous year, the company posted ($0.13) earnings per share. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST/9:30 p.m. GMT to discuss third quarter 2016 financial results and provide a business and financial update. On average, analysts expect that Vertex Pharmaceuticals will post $0.81 EPS for the current fiscal year.
In related news, EVP Stuart A. Arbuckle sold 1,208 shares of the firm's stock in a transaction dated Monday, October 3rd. About 2.58 million shares traded hands or 36.51% up from the average. Following the transaction, the director now directly owns 268,225 shares of the company's stock, valued at approximately $26,873,462.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The stock was sold at an average price of $79.26, for a total transaction of $515,190.00. Following the completion of the sale, the director now owns 274,725 shares in the company, valued at $27,538,434. The disclosure for this sale can be found here. If the company has a ratings score of 1, this would represent a Strong Buy. TimesSquare Capital Management LLC bought a new position in Vertex Pharmaceuticals during the second quarter worth approximately $61,066,000. Stock monthly performance is recorded as -10.27% while its performance in last one week is -1.05%. Analyst forecasts, earnings estimates and price target projections are issued to help their clients make money through stock investments. Shell Asset Mgmt Co, a Netherlands-based fund reported 31,059 shares. LLC boosted its stake in shares of Vertex Pharmaceuticals by 20.7% in the second quarter. Finally, Pictet Asset Management Ltd. increased its position in Vertex Pharmaceuticals by 181.5% in the second quarter. BlueMountain Capital Management LLC now owns 1,867 shares of the pharmaceutical company's stock worth $148,000 after buying an additional 764 shares during the last quarter. The Company is engaged in the business of discovering developing manufacturing and commercializing small molecule drugs.
Jazz Pharmaceuticals Public Limited Company (JAZZ) recently recorded -9.59 percent change and now at $96.74 is -9.36 percent away from its 52-week low and down -39.54 percent versus its peak. In addition to our clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases.